SPAIN | ACTIS
06/11/2019
Lmite 03 Sep 2022
Oferta Tecnolgica
Ref.
TOKR20210805001
A Korean biotech company is looking for potential partners interested in gaining the new therapeutic technology of Rheumatoid Arthritis (RA) drug under a license agreement
A Korean biotech company has developed the new therapeutic technology of Rheumatoid Arthritis (RA) drug, easing the human joint's inflammation by targeting a new recombinant protein. The new recombinant protein helps RA patients recover their damaged joints and increase joint healing. They aim to conduct clinical trials and gain IND (Investigational New Drug) approvals in the U.S. until 2022. The Korean company is looking for biotech partners to gain the new RA drug under a license agreement.
Socios

logotipo CEOE Aragnlogotipo ITAINNOVAlogotipo Cmara Toledologotipo FEDAlogotipo UCLM
logotipo FUNDECYT-PCTEX logotipo ADERlogotipo FERlogotipo AINlogotipo UNAV

06/11/2019

Requerimientos: IE 6.0+, FF 1.5+ 1024x768+ | Aviso Legal | Confidencialidad

06/11/2019